



GlaxoSmithKline Consumer Healthcare Ltd.
24-25 Floor, One Horizon Center
Sector 43, DLF Phase 5, Golf Course Road
Gurugram (Haryana), India - 122002

T +91 124 4336500
F +91 124 4336600
E contact.4.gsk@gsk.com
www.gsk.com

February 12, 2018

The Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

The Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C – 1, Block – G
Bandra-Kurla Complex, Bandra
Mumbai – 400 051

Dear Sir/Madam,

Sub: Unaudited Financial Results for the quarter ended on 31 December 2017

We would like to inform you that the Board of Directors at its meeting held on Monday, February 12, 2018 at 2:00 p.m. at its Corporate office at 24 & 25 Floor, One Horizon Centre, DLF Phase V, Golf Course Road, Gurugram 122 002, have, inter alia, considered and taken on record the unaudited financial results for the quarter ended December 31, 2017. We are enclosing a copy of the Unaudited Financial Results for the quarter ended December 31, 2017 along with the "Limited Review" Certificate, issued by the Statutory Auditors for the review done by them, for your records.

The above may please be taken as our intimation under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking You

Yours faithfully
For GlaxoSmithKline
Consumer Healthcare Limited


Shanu Saksena
Company Secretary
M. No. ACS-13405

CIN: L24231PB1958PLC002257
Registered Office
Patiala Road
Nabha (Punjab), India 147201

GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED

Regd. Office: Patiala Road, Nabha - 147 201 (Punjab).
Head Office: 24th Floor, One Horizon Centre, DLF Phase 5, Golf Course Road, Gurugram- 122 002, Haryana.
Tel. No. 01765-306400; Fax No. 01765-220642

CIN: L24231PB1958PLC002257
Email ID: investor.2.co@gsk.com
Website: www.gsk-ch.in



Statement of Unaudited Results for the Quarter and nine months ended December 31, 2017							(Rs. in Lakhs)
PARTICULARS	For the quarter ended			For the nine months ended		For the year ended	
	31/12/2017	30/09/2017	31/12/2016	31/12/2017	31/12/2016	31/03/2017	
(Refer Notes Below)	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED	
1 Income							
(a) Revenue from operations	10,34,67	11,15,32	9,60,17	31,95,87	32,12,33	44,21,09	
(b) Other income	64,18	54,97	55,92	1,74,84	1,72,92	2,43,88	
Total income	10,98,85	11,70,29	10,16,09	33,70,71	33,85,25	46,64,97	
2 Expenses							
(a) Cost of materials consumed	3,13,71	3,05,59	2,57,62	9,36,06	8,51,03	11,50,75	
(b) Purchase of stock-in-trade	34,96	42,26	41,13	1,07,11	1,06,66	1,53,85	
(c) Changes in inventories of work-in-progress, stock-in-trade and finished goods	(26,34)	46,09	(21,64)	15,71	(37,18)	(7,66)	
(d) Excise duty	-	-	99,78	60,54	3,27,74	4,34,63	
(e) Employee benefits expense	1,33,55	1,29,71	1,06,66	3,97,01	3,54,41	4,58,03	
(f) Depreciation and amortisation expense	15,14	17,68	17,07	49,83	46,48	64,18	
(g) Other expenses							
(i) Advertising and promotion	1,12,53	1,37,10	92,42	3,77,47	3,41,15	5,14,67	
(ii) Others	2,62,25	1,93,21	2,16,51	6,70,25	6,52,10	8,83,33	
(h) Finance costs	17	55	63	1,26	1,91	2,78	
Total Expenses	8,45,97	8,72,19	8,10,18	26,15,24	26,44,30	36,54,56	
3 Profit before tax (1-2)	2,52,88	2,98,10	2,05,91	7,55,47	7,40,95	10,10,41	
4 Income tax expense							
(a) Current tax	85,18	1,02,60	84,43	2,57,66	2,82,22	3,70,24	
(b) Deferred tax	4,04	3,09	(14,93)	9,52	(22,06)	(16,50)	
Total tax expense	89,22	1,05,69	69,50	2,67,18	2,60,16	3,53,74	
5 Profit for the period (3-4)	1,63,66	1,92,41	1,36,41	4,88,29	4,80,79	6,56,67	
6 Other comprehensive income							
(i) Items that will not be reclassified to profit or loss							
Remeasurements of post-employment benefit obligations	2,95	9,88	16,02	12,83	25,40	33,04	
(ii) Income tax relating to items that will not be reclassified to profit or loss	(1,02)	(3,42)	(4,12)	(4,44)	(6,53)	(11,44)	
Total other comprehensive income, net of income tax	1,93	6,46	11,90	8,39	18,87	21,60	
7 Total comprehensive income for the period (5+6)	1,65,59	1,98,87	1,48,31	4,96,68	4,99,66	6,78,27	
8 Paid Up equity share capital	42,06	42,06	42,06	42,06	42,06	42,06	
(Face Value of Equity Shares)	10	10	10	10	10	10	
9 Earnings per share (of Rs 10/- each) (not annualised):							
(a) Basic	38.91	45.75	32.43	116.09	114.31	156.15	
(b) Diluted	38.91	45.75	32.43	116.09	114.31	156.15	

Notes:

- The above results were reviewed by the Audit committee and approved by the Board of Directors in their meeting held on February 12, 2018. Results for the quarter and nine months ended December 31, 2017 have been subjected to limited review by the statutory auditors. The results for the quarter and nine months ended December 31, 2016 and for the year ended March 31, 2017 were subjected to limited review/ audit by the previous statutory auditors.
- The above results have been prepared in accordance with the Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- Consequent to introduction of Goods and Services (GST) with effect from 1st July, 2017. Central Excise, Value Added Tax (VAT) etc. have been subsumed into GST. In accordance with Indian Accounting Standard – 18 on Revenue and Schedule III of the Companies Act, 2013, unlike Excise Duties, levies like GST, VAT, etc. are not part of Revenue. Accordingly, the figures for the periods upto June 30, 2017 are not strictly relatable to those thereafter.
- Based on the guiding principles given in Ind AS 108 on 'Operating segments', the Company's business activity falls within a single operating segment, namely Nutrition. Accordingly, the disclosure requirements of Ind AS 108 are not applicable.

ON BEHAUF OF THE BOARD OF DIRECTORS

N. Sah
Navneet Saluja
Managing Director
DIN: 2183350

Place: Gurugram
Date : February 12, 2018



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM
FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
GlaxoSmithKline Consumer Healthcare Limited**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **GlaxoSmithKline Consumer Healthcare Limited** ("the Company"), for the quarter and nine months ended December 31, 2017 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DELOITTE HASKINS & SELLS LLP

Chartered Accountants

(Firm's Registration No. 117366W/W-100018)


Manjula Banerji
Partner

(Membership No. 086423)

 Gurugram, February 12, 2018